期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 17, 页码 -出版社
MDPI
DOI: 10.3390/ijms22179441
关键词
diabetic retinopathy; diabetic macular edema; angiogenesis; inflammation; glycemic control; pancreatic transplantation; islet cell transplantation; anti-VEGF; corticosteroids
Management of diabetic retinal disease involves glycemic control, intravitreal, and laser therapy. However, challenges remain including frequent hospital visits for intravitreal therapy, limited improvement in vision for some patients, and insufficient evidence to support optimal combinations of treatments. Improved understanding of molecular pathways is leading to the development of novel therapies targeting a range of pathways.
Diabetic retinal disease remains one of the most common complications of diabetes mellitus (DM) and a leading cause of preventable blindness. The mainstay of management involves glycemic control, intravitreal, and laser therapy. However, intravitreal therapy commonly requires frequent hospital visits and some patients fail to achieve a significant improvement in vision. Novel and long-acting therapies targeting a range of pathways are warranted, while evidence to support optimal combinations of treatments is currently insufficient. Improved understanding of the molecular pathways involved in pathogenesis is driving the development of therapeutic agents not only targeting visible microvascular disease and metabolic derangements, but also inflammation and accelerated retinal neurodegeneration. This review summarizes the current and emerging treatments of diabetic retinal diseases and provides an insight into the future of managing this important condition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据